Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples